approval
saveKEYTRUDA (PEMBROLIZUMAB) — FDA approval
community read0 votes
Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 2 completionMerck & Co Inc — pembrolizumab (Phase II Trial Completion)Apr 30, 2026 · 155d ago
- phase 1 initiationNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)Apr 27, 2026 · 158d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalApr 6, 2026 · 179d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalFeb 10, 2026 · 234d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalNov 21, 2025 · 315d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJul 24, 2025 · 435d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJun 12, 2025 · 477d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJun 6, 2025 · 483d ago
same company · ±60 days · 5
- approvalpembrolizumab: KEYTRUDA (PEMBROLIZUMAB) — FDA approvalDec 18, 2015
- approvalPOSACONAZOLE: NOXAFIL (POSACONAZOLE) — FDA approvalNov 13, 2015
- approvalPOSACONAZOLE: NOXAFIL (POSACONAZOLE) — FDA approvalNov 13, 2015
- approvalPOSACONAZOLE: NOXAFIL (POSACONAZOLE) — FDA approvalNov 13, 2015
- approvalPOSACONAZOLE: NOXAFIL (POSACONAZOLE) — FDA approvalNov 13, 2015
🐶 often sniffed alongside
top 8- drugKEYTRUDA515 co-mentions · 131 sources
- tagApproval512 co-mentions · 128 sources
- drugKEYTRUDA QLEX269 co-mentions · 131 sources
- drugCancer Program256 co-mentions · 128 sources
- drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
- tagGlioblastoma2 co-mentions · 1 sources
- drugaxelopran1 co-mentions · 1 sources
- companyNational Institute of Neurological Disorders and Stroke1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that